These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34363746)

  • 1. Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Systemic Lupus Erythematosus and Rheumatoid Arthritis: Results of a Quality Improvement Initiative.
    Skorupa T; Shmerling RH
    ACR Open Rheumatol; 2021 Oct; 3(10):733-737. PubMed ID: 34363746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of an electronic medical record intervention on hydroxychloroquine prescribing habits and surveyed providers' opinions of the 2016 American Academy of Ophthalmology guidelines in the rheumatology and dermatology practices of an academic institutionle.
    Overbury RS; Stoddard GJ; Pupaibool J; Hansen CB; Lebiedz-Odrobina D
    BMC Health Serv Res; 2021 Sep; 21(1):913. PubMed ID: 34479563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatologists' perspective on hydroxychloroquine guidelines.
    Winebrake J; Khalili L; Weiner J; Gartshteyn Y; Park L; Askanase AD
    Lupus Sci Med; 2020 Nov; 7(1):. PubMed ID: 33148665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2-3 mg/kg/day): 12-month prospective randomized controlled trial.
    Zanetti CB; Pedrosa T; Kupa LVK; Aikawa NE; Borba EF; Vendramini MBG; Silva CA; Pasoto SG; Bonfa E
    Clin Rheumatol; 2021 Jul; 40(7):2745-2751. PubMed ID: 33486596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients.
    Pedrosa T; Kupa LVK; Pasoto SG; Aikawa NE; Borba EF; Duarte NJ; Leon EP; Silva CA; Bonfá E
    Lupus; 2021 Apr; 30(4):554-559. PubMed ID: 33402039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016.
    Melles RB; Jorge AM; Marmor MF; Zhang Y; Choi HK
    Clin Rheumatol; 2018 Jul; 37(7):1853-1859. PubMed ID: 29696437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System.
    Braslow RA; Shiloach M; Macsai MS
    Ophthalmology; 2017 May; 124(5):604-608. PubMed ID: 28153440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.
    Jorge AM; Melles RB; Zhang Y; Lu N; Rai SK; Young LH; Costenbader KH; Ramsey-Goldman R; Lim SS; Esdaile JM; Clarke AE; Urowitz MB; Askanase A; Aranow C; Petri M; Choi H
    Arthritis Res Ther; 2018 Jul; 20(1):133. PubMed ID: 29976231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving eye screening practice among pediatric rheumatology patients receiving hydroxychloroquine.
    AlAhmed O; Way A; Akoghlanian S; Barbar-Smiley F; Lemle S; MacDonald D; Frost E; Wise K; Lee L; Ardoin SP; Sivaraman V
    Lupus; 2021 Feb; 30(2):269-279. PubMed ID: 33307983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.
    Al-Rawi H; Meggitt SJ; Williams FM; Wahie S
    Lupus; 2018 Apr; 27(5):847-852. PubMed ID: 28862574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence.
    Osmani Z; Schrama TJ; Zacouris-Verweij W; Andersen J; Frankel S; Bultink IEM; Cornet A; van Vollenhoven RF
    Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33795484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.
    Durcan L; Clarke WA; Magder LS; Petri M
    J Rheumatol; 2015 Nov; 42(11):2092-7. PubMed ID: 26428205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An audit of the use of hydroxychloroquine in rheumatology clinics.
    Worth C; Yusuf IH; Turner B; Gourier H; Brooks EE; Mort DO; Sharma S; Downes SM; Luqmani RA
    Rheumatol Adv Pract; 2018; 2(1):rky013. PubMed ID: 31431961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
    Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
    Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease.
    Bethel M; Yang FM; Li S; Nahman NS; Oliver AM; Machua W; Carbone LD
    J Investig Med; 2016 Apr; 64(4):908-10. PubMed ID: 26911274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.
    Penn SK; Kao AH; Schott LL; Elliott JR; Toledo FG; Kuller L; Manzi S; Wasko MC
    J Rheumatol; 2010 Jun; 37(6):1136-42. PubMed ID: 20436082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.
    Gianfrancesco MA; Schmajuk G; Haserodt S; Trupin L; Izadi Z; Jafri K; Shiboski S; Sirota M; Dudley RA; Yazdany J
    Rheumatol Int; 2017 Oct; 37(10):1611-1618. PubMed ID: 28748425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
    Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
    Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Hydroxychloroquine Dosing and Toxicity Screening at a Tertiary Care Ambulatory Center: A Quality Improvement Initiative.
    Koppikar S; Gottheil S; Farrer C; Gakhal N
    J Rheumatol; 2021 Jan; 48(1):138-144. PubMed ID: 32238522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.